IDP-001 / InduPro - LARVOL DELTA

Pre-Clinical Characterization of IDP-001, a First-in-Class EGFRxCDCP1 Bispecific Antibody Drug Conjugate for Lung Cancer (IASLC-WCLC 2026) - "Conclusions : IDP-001 was designed to leverage the co-expression and spatial proximity of EGFR and CDCP1 frequently found in tumors, thereby increasing tumor-selective cytotoxicity. Collectively, preclinical data presented here support the investigational use of IDP-001 as a targeted anticancer therapy with a differentiated mechanism based on dual EGFR/CDCP1 targeting and enhanced antitumor activity."

ADC • Bispecific • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • CDCP1

InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001 (Businesswire) - "Proceeds from the financing will support Phase 1 clinical development and generation of early proof-of-concept data for IDP-001, as well as the advancement of InduPro’s broader preclinical pipeline.....The open-label, first-in-human study (NCT07602842) is evaluating the safety, tolerability, pharmacokinetics and preliminary antitumor activity of IDP-001 as monotherapy in adults with advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC) and other squamous solid tumors with disease progression following standard-of-care treatment."

Financing • First-in-human • Trial status • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer

A Study of IDP-001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=132 | Recruiting | Sponsor: InduPro, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Anal Carcinoma • Cervical Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer

A Study of IDP-001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1/2 | N=132 | Not yet recruiting | Sponsor: InduPro, Inc.

New P1/2 trial • Anal Carcinoma • Cervical Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer

Membrane interactomics (MInt) platform identifies EGFR and CDCP1 as effective co-targets for bispecific antibody drug conjugate IDP-001 (AACR 2025) - "IDP-001 is effective in vitro against a panel of cancer cell lines of varying target expression levels, including Osimertinib resistant EGFR mutant NSCLC. 3) Law ME, et al. Breast Cancer Res 18 (2016) 80."

ADC • Bispecific • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CDCP1 • EGFR

Discovery and optimization of IDP-001, a bispecific ADC targeting EGFR and CDCP1 (AACR 2025) - "IDP-001 has potent in vitro cytotoxic activity against cancer cell lines with varying target expression levels. IDP-001 is a first-in-class bispecific ADC with the potential for a wider therapeutic window and best-in-class efficacy."

ADC • Bispecific • Oncology • CDCP1 • EGFR

Application of a membrane interactomics (MInt) platform for novel surface target discovery (AACR 2025) - "This platform has led to multiple preclinical programs, including IDP-001, a bispecific ADC targeting EGFR and CDCP1 in solid tumors.Here, we showcase our discovery engine for novel target identification as a powerful method for uncovering druggable protein targets with improved therapeutic windows. This approach has the potential to expand the repertoire of cancer targets and enable the next generation of bispecific therapeutics."

Oncology • Solid Tumor • CDCP1 • EGFR

IDP-001 is a potent bispecific ADC with in vivo activity against mouse xenograft tumor models expressing EGFR and CDCP1 (AACR 2025) - "IDP-001 is a first-in-class bispecific ADC with the potential for broad therapeutic activity and best-in-class efficacy. These encouraging in vivo results support advancement of IDP-001 to non-human primate studies."

ADC • Bispecific • Preclinical • Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • CDCP1 • EGFR